BackgroundThe requirement for luteal phase support (LPS) in stimulated IVF cycles is well established, however drug choice, and route of administration and duration of use are not. This report evaluates patients’ preference and satisfaction by using either vaginal or intramuscular (IM) progesterone (P) supplementation for luteal phase support after in vitro fertilization and embryo transfer (IVF-ET).MethodsIt is a prospective cohort study done in a reproductive and infertility unit in a tertiary care hospital from March 2013 through February 2015 for four hundred and nine patients undergoing IVF-ET. Patients were allowed to choose either vaginal or IM P for LPS. Patient preference and satisfaction, as well as differences in clinical pregnancy rates between the two groups were assessed at one or two time points throughout the study.ResultsThere were no statistically significant differences in the patients’ characteristics and clinical outcomes between the two groups. There were 88 pregnancies (38.8%) among patients treated with vaginal p and 62 pregnancies (34%) among IM P patients. Average satisfaction score at the pregnancy test and ultrasound (U/S) visits was similar between both groups.ConclusionsPatients’ satisfaction and pregnancy rates were similar between vaginal and IM P supplementation.
respectively. A similar, decreasing trend in LBR was observed for implantation rate (IR) and clinical pregnancy rate (CPR) in all BMI categories outside referent in women with a blastocyst ET. The AOR for reproductive outcomes for blastocyst ET (n¼32,115) are shown in Table 1.CONCLUSIONS: In this large, nationwide cohort study in women with a fresh IVF-ET extremes of pre-treatment maternal BMI was a significant negative predictor for IVF outcomes.IMPACT STATEMENT: This study highlights the influence of extremely underweight women and those with obesity class I, II, and III on IVF outcomes. Further research on the broader implications of IVF in women with BMI < 17.5 and >45 should be pursued.
Introduction: The Coronavirus disease 2019 (COVID-19) vaccine has been approved by the United States Food and Drug Administration as safe and effective against the virus. In addition to the vaccine known adverse effects, a lot of women worldwide have experienced abnormal uterine bleeding (AUB) after receiving the COVID-19 vaccine. This study aimed to figure out the relationship between AUB and the COVID-19 vaccine and to compare the effects of different vaccine types on AUB. Methods: An e-questionnaire-based cross-sectional study conducted between December 2021 to February 2022. The targeted population of the study was all COVID-19 vaccinated female in Saudi Arabia. A total of 1912 respondents participated in the survey, only 1533 were eligible for inclusion in the study. The collected data were analyzed using descriptive statistical methods via Statistical Packages for Social Sciences version 26. Result: Out of 1533 participants, 998 (64.4%) reported AUB in relation to the COVID-19 vaccine. The mean age of the participants was 31.2±8.4 years, and more than half of them (59.4%) were married. Majority had received the Pfizer-BioNTech vaccine in their three shots (77.1%), (78%), and (92.1%), respectively. The incidence of AUB was (82.7%) mainly in form of menorrhagia (38.3%) in the first shot and (88.8%) after the second dose also in the form of menorrhagia (39.1%). Only 3.8% of women had the third dose, the incidence of AUB was 65.8%, mainly in the form of oligomenorrhea (21.1%). Regarding different types of the vaccine in three doses, the Chi-square test (p=0.239), (p=0.200) and Fischer exact test (p=0.265) were statistically significant showing no difference in AUB with different COVID-19 vaccines. Conclusion: The majority of participants had AUB as a result of receiving the COVID-19 vaccine. Furthermore, there was no difference in the incidence of AUB between the Pfizer-BioNTech vaccination and the AstraZeneca Oxford vaccine for the two vaccine types investigated in the study.
Background: Ovarian tumors are the second most cause of cancer-related
mortality in women, with a wide range of histological diagnoses. It is
responsible for 6% of all malignancies. Despite the fact that it is one
of the curable tumors due to its susceptibility to anticancer medicines,
it seldom causes symptoms until the disease has progressed widely. The
goal of our research is to establish the type of various ovarian tumors
as well as the frequency and distribution of various neoplastic lesions
in the past. Methods: 201 ovarian tumors were retrospectively collected
from 8691 gynecology cases seen in the outpatient clinic at the
maternity and children’s hospital in Al Madinah Al Munawara, Saudi
Arabia [from January 2015 to January 2019] to determine the
frequency of different histological patterns of ovarian tumors in our
hospital. Results: The majority of ovarian tumor cases, 186 cases,
(92.54 percent) were benign, although 13 cases (6.47 percent) were
malignant, and the other two cases were borderline (1%). Epithelial
tumors were the most prevalent histological pattern seen in the
investigation (69.8 percent). Serous cyst adenoma and teratoma were the
most prevalent benign tumors, whereas serous cystadenocarcinoma and
mucinous cystadenocarcinoma were the most common malignant tumors.
Conclusion: Epithelial tumors are the most prevalent ovarian tumors in
our study. Germ cell tumors were in second place, followed by epithelial
ovarian tumors, which are more prevalent in adults and adolescents.
Patients with malignant ovarian tumors frequently come in later stages
of the disease, hence late reporting is prevalent.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.